M. Munder

发表

Suppression of T-cell functions by human granulocyte arginase.

A. Kolb, T. Giese, A. Ho, 2006, Blood.

Arginase: an emerging key player in the mammalian immune system

M. Munder, 2009, British journal of pharmacology.

Murine Macrophages Secrete Interferon γ upon Combined Stimulation with Interleukin (IL)-12 and IL-18: A Novel Pathway of Autocrine Macrophage Activation

Klaus Eichmann, Moisés Mallo, M. Munder, 1998, The Journal of experimental medicine.

Lethal systemic and brain infection caused by Prototheca zopfii algae in a patient with acute myeloid leukemia

M. Munder, E. Siegel, A. Kreft, 2021, Medical mycology case reports.

Malnutrition in Healthy Individuals Results in Increased Mixed Cytokine Profiles, Altered Neutrophil Subsets and Function

Z. Shkedy, J. Raynes, I. Müller, 2016, PloS one.

Local Suppression of T Cell Responses by Arginase-Induced L-Arginine Depletion in Nonhealing Leishmaniasis

R. Titus, I. Müller, M. Munder, 2009, PLoS neglected tropical diseases.

l-Arginine deprivation impairs Leishmania major-specific T-cell responses

M. Munder, P. Kropf, Matthew E. Rogers, 2009, European journal of immunology.

Differential impact of l-arginine deprivation on the activation and effector functions of T cells and macrophages

I. Müller, M. Munder, P. Kropf, 2008, Journal of leukocyte biology.

Teaming up for CAR-T cell therapy

R. Wäsch, M. Munder, R. Marks, 2019, Haematologica.

Peripheral neuropathy associated with subcutaneous or intravenous bortezomib in patients with newly diagnosed myeloma treated within the GMMG MM5 phase III trial

D. Hose, H. Goldschmidt, A. Jauch, 2016, Haematologica.

Disease severity in patients with visceral leishmaniasis is not altered by co-infection with intestinal parasites

Z. Shkedy, J. Raynes, I. Müller, 2017, PLoS neglected tropical diseases.

Induced arginine transport via cationic amino acid transporter‐1 is necessary for human T‐cell proliferation

E. Closs, M. Munder, J. Rupp, 2016, European journal of immunology.

Δ133p53α enhances metabolic and cellular fitness of TCR-engineered T cells and promotes superior antitumor immunity

J. Bourdon, D. Galetzka, M. Hundemer, 2021, Journal for ImmunoTherapy of Cancer.

Evaluation of Cardiac Repolarization in the Randomized Phase 2 Study of Intermediate- or High-Risk Smoldering Multiple Myeloma Patients Treated with Daratumumab Monotherapy

H. Goldschmidt, M. Boccadoro, M. Jenner, 2021, Advances in Therapy.

Highly Efficient Expansion of Human CD4+CD25+ Regulatory T Cells for Cellular Immunotherapy in Patients with Graft-Versus-Host Disease

A. Ho, M. Munder, Markus Schneider, 2006, Journal of immunotherapy.

Inhibition of Arginase 1 Liberates Potent T Cell Immunostimulatory Activity of Human Neutrophil Granulocytes

S. Tenzer, M. Bros, E. Closs, 2021, Frontiers in Immunology.

Low Levels of Prothrombin Time (INR) and Platelets Do Not Increase the Risk of Significant Bleeding when Placing Central Venous Catheters*

J. Encke, W. Stremmel, A. Zahn, 2009, Medizinische Klinik.

Characterization of Neutrophil Subsets in Healthy Human Pregnancies

N. Kiwanuka, I. Müller, L. Kindinger, 2014, PloS one.

Arginine deficiency leads to impaired cofilin dephosphorylation in activated human T lymphocytes.

A. Ho, Y. Samstag, M. Schiller, 2012, International immunology.

Challenges in the cultural adaptation of the German Myeloma Patient Outcome Scale (MyPOS): an outcome measure to support routine symptom assessment in myeloma care

C. Ramsenthaler, M. Munder, C. Gerlach, 2019, BMC Cancer.

Monoclonal gammopathy of ocular significance (MGOS) – a short survey of corneal manifestations and treatment outcomes

D. Vesole, M. Munder, A. Waszczuk-Gajda, 2021, Leukemia and Lymphoma.

polymorphonuclear leukocytes? A and B or perforin: similarities or differences with human Quiescent and activated mouse granulocytes do not express granzyme

M. Simon, R. Wallich, M. Munder, 2013 .

Quiescent and activated mouse granulocytes do not express granzyme A and B or perforin: similarities or differences with human polymorphonuclear leukocytes?

M. Simon, R. Wallich, M. Munder, 2005, Blood.

Arginase I is constitutively expressed in human granulocytes and participates in fungicidal activity.

A. Ho, J. M. Fuentes, F. Mollinedo, 2005, Blood.

A randomized phase III study of carfilzomib vs low-dose corticosteroids with optional cyclophosphamide in relapsed and refractory multiple myeloma (FOCUS)

M. Dimopoulos, A. Palumbo, D. Rossi, 2016, Leukemia.

Human eosinophil granulocytes do not express the enzyme arginase

J. Hohlfeld, A. Ho, M. Schiller, 2010, Journal of leukocyte biology.

Depletion of L-arginine induces autophagy as a cytoprotective response to endoplasmic reticulum stress in human T lymphocytes

F. Mollinedo, M. Munder, R. García-Navas, 2012, Autophagy.

Successful Treatment of Human Visceral Leishmaniasis Restores Antigen-Specific IFN-γ, but not IL-10 Production

Z. Shkedy, I. Müller, M. Munder, 2016, PLoS neglected tropical diseases.

Regulation of NK Cell Function by Human Granulocyte Arginase1

T. Giese, A. Ho, I. Müller, 2009, The Journal of Immunology.

Cereblon-binding proteins expression levels correlate with hyperdiploidy in newly diagnosed multiple myeloma patients

D. Hose, H. Goldschmidt, A. Jauch, 2019, Blood Cancer Journal.

The prognostic and predictive value of IKZF1 and IKZF3 expression in T-cells in patients with multiple myeloma

H. Goldschmidt, J. Dürig, C. Müller-Tidow, 2017, Oncoimmunology.

Isatuximab, carfilzomib, lenalidomide, and dexamethasone (Isa-KRd) in front-line treatment of high-risk multiple myeloma: interim analysis of the GMMG-CONCEPT trial

H. Goldschmidt, A. Jauch, Y. Ko, 2021, Leukemia.

Polymorphonuclear neutrophils and T lymphocytes: strange bedfellows or brothers in arms?

I. Müller, M. Munder, P. Kropf, 2009, Trends in immunology.

Dendritic Cells Isoforms in Murine Macrophages and Th 1 / Th 2-Regulated Expression of Arginase

M. Munder, M. Modolell, J. Morán, 1999 .

Th1/Th2 Phenotype T Cells Correlates with + Regulation by CD4 Synthase/Arginase Balance: Competitive Macrophages Reflected by the Nitric Oxide Alternative Metabolic States in Murine

M. Munder, M. Modolell, K. Eichmann, 1998 .

Role of arginase in asthma: potential clinical applications

M. Munder, 2010, Expert review of clinical pharmacology.

A Role for Toll-Like Receptor Mediated Signals in Neutrophils in the Pathogenesis of the Anti-Phospholipid Syndrome

H. Schild, K. Lackner, I. Scharrer, 2012, PloS one.

Arginase activity mediates reversible T cell hyporesponsiveness in human pregnancy

S. Marshall, J. M. Fuentes, I. Müller, 2007, European journal of immunology.

Arginine deﬁciency leads to impaired coﬁlin dephosphorylation in activated human T lymphocytes

Y. Samstag, M. Schiller, G. Wabnitz, 2012 .

Identification of Novel Rare ABCC1 Transporter Mutations in Tumor Biopsies of Cancer Patients

T. Efferth, O. Kadioglu, M. Saeed, 2020, Cells.

T cell response in experimental autoimmune encephalomyelitis (EAE): role of self and cross-reactive antigens in shaping, tuning, and regulating the autopathogenic T cell repertoire.

V. Kuchroo, E. Bettelli, M. Munder, 2002, Annual review of immunology.

Increased level of arginase activity correlates with disease severity in HIV-seropositive patients.

I. Müller, M. Munder, P. Kropf, 2010, The Journal of infectious diseases.

Characterization of a Novel Population of Low-Density Granulocytes Associated with Disease Severity in HIV-1 Infection

I. Müller, M. Munder, P. Kropf, 2012, PloS one.

Phenotypic Alteration of Neutrophils in the Blood of HIV Seropositive Patients

I. Müller, M. Munder, P. Kropf, 2013, PloS one.

Addition of isatuximab to lenalidomide, bortezomib, and dexamethasone as induction therapy for newly diagnosed, transplantation-eligible patients with multiple myeloma (GMMG-HD7): part 1 of an open-label, multicentre, randomised, active-controlled, phase 3 trial.

H. Goldschmidt, E. Nievergall, T. Holderried, 2022, The Lancet. Haematology.

J. M. Fuentes, I. Müller, M. Munder, 2008, PLoS neglected tropical diseases.

Arginase Activity - A Marker of Disease Status in Patients with Visceral Leishmaniasis in Ethiopia

I. Müller, F. Tacchini-Cottier, E. Closs, 2013, PLoS neglected tropical diseases.

Overall Survival With Daratumumab, Bortezomib, and Dexamethasone in Previously Treated Multiple Myeloma (CASTOR): A Randomized, Open-Label, Phase III Trial

P. Sonneveld, A. Chanan-Khan, A. Nooka, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Daratumumab, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma: subgroup analysis of CASTOR based on cytogenetic risk

P. Sonneveld, A. Chanan-Khan, H. Avet-Loiseau, 2020, Journal of Hematology & Oncology.

Comparison of NGS and MFC Methods: Key Metrics in Multiple Myeloma MRD Assessment

H. Goldschmidt, C. Müller-Tidow, R. Fenk, 2020, Cancers.

Novel immunotherapies in multiple myeloma – chances and challenges

H. Goldschmidt, R. Wäsch, M. Munder, 2021, Haematologica.

Prevalence of corneal findings and their interrelation with hematological findings in monoclonal gammopathy

A. Schuster, M. Munder, J. Wasielica-Poslednik, 2022, PloS one.

Arginase Activity in the Blood of Patients with Visceral Leishmaniasis and HIV Infection

I. Müller, F. Tacchini-Cottier, M. Munder, 2013, PLoS neglected tropical diseases.

Oral Sessions

Capasso, A. Cantone, F. Artunc, 2014 .

Metabolism via Arginase or Nitric Oxide Synthase: Two Competing Arginine Pathways in Macrophages

I. Müller, E. Closs, M. Munder, 2014, Front. Immunol..

Monocyte dependent regulation of autoimmune inflammation.

M. Munder, L. Nicholson, B. Raveney, 2009, Current molecular medicine.

Visceral Leishmaniasis Patients Display Altered Composition and Maturity of Neutrophils as well as Impaired Neutrophil Effector Functions

V. Yardley, G. Van der Auwera, I. Müller, 2016, Front. Immunol..

Addition of cyclophosphamide on insufficient response to pomalidomide and dexamethasone: results of the phase II PERSPECTIVE Multiple Myeloma trial

D. Hose, H. Goldschmidt, A. Jauch, 2019, Blood Cancer Journal.

Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma.

A. Palumbo, P. Sonneveld, A. Chanan-Khan, 2016, The New England journal of medicine.

SAMHD1 in cancer: curse or cure?

R. König, Mirko H. H. Schmidt, K. Rajalingam, 2021, Journal of Molecular Medicine.

Response-adapted lenalidomide maintenance in newly diagnosed myeloma: results from the phase III GMMG-MM5 trial

D. Hose, H. Goldschmidt, A. Jauch, 2020, Leukemia.

Correlation between Increased Arginase Activity Levels and Disease Severity in HIV-Seropositive Patients

M. Munder, P. Kropf, G. Taylor, 2015 .

Cytotoxicity of Tumor Antigen Specific Human T Cells Is Unimpaired by Arginine Depletion

H. Goldschmidt, A. Ho, Y. Samstag, 2013, PloS one.

Local Increase of Arginase Activity in Lesions of Patients with Cutaneous Leishmaniasis in Ethiopia

Nafisa-Katrin Seich al Basatena, I. Müller, F. Tacchini-Cottier, 2012, PLoS neglected tropical diseases.

Effect of ABC transporter expression and mutational status on survival rates of cancer patients.

T. Efferth, O. Kadioglu, M. Saeed, 2020, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

Subcutaneous versus intravenous bortezomib in two different induction therapies for newly diagnosed multiple myeloma: an interim analysis from the prospective GMMG-MM5 trial

D. Hose, H. Goldschmidt, A. Jauch, 2015, Haematologica.

Protein energy malnutrition increases arginase activity in monocytes and macrophages

V. Yardley, I. Müller, M. Munder, 2014, Nutrition & Metabolism.

Prognostic Impact of Serum Free Light Chain Ratio Normalization in Patients with Multiple Myeloma Treated within the GMMG-MM5 Trial

D. Hose, H. Goldschmidt, A. Jauch, 2021, Cancers.

Long-term follow-up of subcutaneous versus intravenous bortezomib during induction therapy for newly diagnosed multiple myeloma treated within the GMMG-MM5 Phase III Trial

D. Hose, H. Goldschmidt, A. Jauch, 2021, Leukemia.

Lenalidomide versus bortezomib maintenance after frontline autologous stem cell transplantation for multiple myeloma

D. Hose, H. Goldschmidt, A. Jauch, 2021, Blood Cancer Journal.

Lenalidomide versus bortezomib maintenance after frontline autologous stem cell transplantation for multiple myeloma

D. Hose, H. Goldschmidt, A. Jauch, 2021, Blood cancer journal.

Bortezomib-based induction therapy with high or low-dose dexamethasone in newly diagnosed, transplant-eligible multiple myeloma

D. Hose, H. Goldschmidt, A. Jauch, 2018, Leukemia.

Phase III trial of bortezomib, cyclophosphamide and dexamethasone (VCD) versus bortezomib, doxorubicin and dexamethasone (PAd) in newly diagnosed myeloma

D. Hose, H. Goldschmidt, A. Jauch, 2015, Leukemia.

GMMG MM5 Trial In Newly Diagnosed Multiple Myeloma To Evaluate PAd Vs VCD Induction Prior To High Dose Treatment Followed By Lenalidomide Consolidation and Maintenance – Final Analysis On Induction Therapy

D. Hose, H. Goldschmidt, A. Jauch, 2013 .

Alternative metabolic states in murine macrophages reflected by the nitric oxide synthase/arginase balance: competitive regulation by CD4+ T cells correlates with Th1/Th2 phenotype.

M. Munder, M. Modolell, K. Eichmann, 1998, Journal of immunology.

Elotuzumab in Combination with Lenalidomide, Bortezomib, Dexamethasone and Autologous Transplantation for Newly-Diagnosed Multiple Myeloma: Results from the Randomized Phase III GMMG-HD6 Trial

D. Hose, H. Goldschmidt, A. Jauch, 2021, Blood.

Addition of Isatuximab to Lenalidomide, Bortezomib and Dexamethasone As Induction Therapy for Newly-Diagnosed, Transplant-Eligible Multiple Myeloma Patients: The Phase III GMMG-HD7 Trial

H. Goldschmidt, E. Nievergall, T. Holderried, 2021, Blood.

Th1/Th2-regulated expression of arginase isoforms in murine macrophages and dendritic cells.

K Eichmann, M. Munder, M. Modolell, 1999, Journal of immunology.

Repurposing of the ALK Inhibitor Crizotinib for Acute Leukemia and Multiple Myeloma Cells

S. Klauck, T. Efferth, M. Saeed, 2021, Pharmaceuticals.

Addition of Cyclophosphamide to Pomalidomide and Dexamethasone in Case of Suboptimal Response to Pomalidomide and Dexamethasone Alone in Relapsed and/or Refractory Multiple Myeloma: Results of the GMMG-Perspective Trial

D. Hose, H. Goldschmidt, A. Jauch, 2017 .

The initial phase of graft-versus-host disease is associated with a decrease of CD4+CD25+ regulatory T cells in the peripheral blood of patients after allogeneic stem cell transplantation.

A. Ho, M. Munder, S. Karakhanova, 2006, Clinical and laboratory haematology.

Cationic Amino Acid Transporter-1-Mediated Arginine Uptake Is Essential for Chronic Lymphocytic Leukemia Cell Proliferation and Viability

K. Rajalingam, E. Closs, M. Munder, 2019, Front. Oncol..

Selective elimination of immunosuppressive T cells in patients with multiple myeloma

H. Goldschmidt, A. Jauch, B. Brors, 2021, Leukemia.

Rationale and design of the German-speaking myeloma multicenter group (GMMG) trial HD6: a randomized phase III trial on the effect of elotuzumab in VRD induction/consolidation and lenalidomide maintenance in patients with newly diagnosed myeloma

D. Hose, H. Goldschmidt, A. Jauch, 2019, BMC Cancer.

Implications and prognostic impact of mass spectrometry in patients with newly-diagnosed multiple myeloma

D. Hose, H. Goldschmidt, A. Jauch, 2022, Blood Cancer Journal.

Bortezomib-based induction, high-dose melphalan and lenalidomide maintenance in myeloma up to 70 years of age

D. Hose, H. Goldschmidt, A. Jauch, 2020, Leukemia.

Depth of Response to Isatuximab, Carfilzomib, Lenalidomide and Dexamethasone (Isa-KRd) in Front-Line Treatment of High-Risk Multiple Myeloma: Interim Analysis of the GMMG-CONCEPT Trial

H. Goldschmidt, A. Jauch, Y. Ko, 2021, SSRN Electronic Journal.

Macrophage: SHIP of Immunity

L. Lenz, M. Munder, Anita C. Thomas, 2014, Front. Immunol..

Granulocyte functions are independent of arginine availability

T. Giese, J. Bomalaski, I. Müller, 2014, Journal of leukocyte biology.

Reconstitution of T Cell Proliferation under Arginine Limitation: Activated Human T Cells Take Up Citrulline via L-Type Amino Acid Transporter 1 and Use It to Regenerate Arginine after Induction of Argininosuccinate Synthase Expression

E. Closs, M. Munder, J. Rupp, 2017, Front. Immunol..

P. Sonneveld, A. Nooka, T. Renaud, 2021, British journal of haematology.

Response-Adapted Lenalidomide Maintenance in Newly Diagnosed, Transplant-Eligible Multiple Myeloma: Results from the Multicenter Phase III GMMG-MM5 Trial

D. Hose, H. Goldschmidt, A. Jauch, 2017 .

DARATUMUMAB, BORTEZOMIB AND DEXAMETHASONE (DVD) VS BORTEZOMIB AND DEXAMETHASONE (VD) IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM): EFFICACY AND SAFETY UPDATE (CASTOR)

P. Sonneveld, M. Munder, T. Casneuf, 2017 .

Cereblon-binding proteins expression levels correlate with hyperdiploidy in newly diagnosed multiple myeloma patients

D. Hose, H. Goldschmidt, A. Jauch, 2019, Blood Cancer Journal.

Direct stimulation of macrophages by IL-12 and IL-18 - a bridge built on solid ground.

M. Munder, M. Modolell, M. Mallo, 2001, Immunology letters.

D. Hose, H. Goldschmidt, A. Jauch, 2019, BMC Cancer.

Addition of cyclophosphamide on insufficient response to pomalidomide and dexamethasone: results of the phase II PERSPECTIVE Multiple Myeloma trial

D. Hose, H. Goldschmidt, A. Jauch, 2019, Blood Cancer Journal.

Reduced Self-Reactivity of an Autoreactive T Cell After Activation with Cross-reactive Non–Self-Ligand

Lindsay B. Nicholson, Vijay K. Kuchroo, V. Kuchroo, 2002, The Journal of experimental medicine.

[Infusion of Daratumumab in Combination Therapies - Practical Information for The Outpatient Area].

C. Scheid, M. Munder, M. Engelhardt, 2018, Deutsche medizinische Wochenschrift.

A drug repurposing approach for individualized cancer therapy based on transcriptome sequencing and virtual drug screening

T. Efferth, O. Kadioglu, N. Mahmoud, 2023, Comput. Biol. Medicine.

SHIP of Immunity. Frontiers in Immunology, 5,

L. Lenz, M. Munder, Charles D. Mills, 2014 .

SHIP of Immunity. Frontiers in Immunology, 5,

L. Lenz, M. Munder, Charles D. Mills, 2014 .

Isatuximab, Carfilzomib, Lenalidomide, and Dexamethasone for the Treatment of High-Risk Newly Diagnosed Multiple Myeloma

A. Jauch, Y. Ko, C. Scheid, 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

P930: ISATUXIMAB, LENALIDOMIDE, BORTEZOMIB AND DEXAMETHASONE AS INDUCTION THERAPY FOR NEWLY-DIAGNOSED MULTIPLE MYELOMA PATIENTS WITH HIGH-RISK CYTOGENETICS: A SUBGROUP ANALYSIS FROM THE GMMG-HD7 TRIAL

Michael J. Hoffmann, E. Nievergall, J. Dürig, 2022, HemaSphere.